Cytokine engineering for targeted cancer immunotherapy

Curr Opin Chem Biol. 2021 Mar 5;62:43-52. doi: 10.1016/j.cbpa.2021.01.007. Online ahead of print.ABSTRACTCytokines are key modulators of the immune responses and represent promising therapeutics for a variety of cancers. However, successful translation of cytokine-based therapy to the clinic is limited by, among others, severe toxicities and lack of efficacy due to cytokine pleiotropy and off-target activation of cells. Engineering cytokines with enhanced therapeutic properties has emerged as a promising strategy to overcome these challenges. Advances in protein engineering and protein-polymer conjugate technologies have fostered the generation of cytokines with enhanced target cell specificity and longer half-life than the native ones. These novel cytokines exhibit reduced systemic toxicities while focusing the activities at the tumor site, thus, enhancing antitumor immunity. The growing toolbox of cytokine engineering strategies will further stimulate the development of smart cytokine-based immunotherapies with enhanced efficacy and safety profiles.PMID:33684633 | DOI:10.1016/j.cbpa.2021.01.007
Source: Current Opinion in Chemical Biology - Category: Biochemistry Authors: Source Type: research